Results 201 to 210 of about 3,419,452 (348)
Molecular Oncology, EarlyView.This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani +14 more
wiley +1 more source
Pressure-Induced Structural Phase Transition in EuNi2P2
ACS Omega, 2022 Xuehui Wei, Jianzong Wang
doaj +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Topological phase transition in monolayer 1[Formula: see text]-[Formula: see text]. [PDF]
Sci RepNobahari MM, Roknabadi MR.
europepmc +1 more source
THE CRYSTAL STRUCTURE AND PHASE TRANSITIONS OF β-Zn2P2O7 [PDF]
, 1965 C. Calvo
openalex +1 more source
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen +12 more
wiley +1 more source
Influence of misfit dislocations on the phase transition of iron(iii) oxides. [PDF]
Nanoscale AdvHoang VH, Lee NS, Kim HJ.
europepmc +1 more source